Shengda Bio announced plans to repurchase part of its A-shares through centralized bidding using its own funds or self-raised funds, with a repurchase amount of no less than 16.5 million yuan and no more than 30 million yuan. The maximum repurchase price is 15 yuan per share, and the expected number of shares to be repurchased ranges from 1.1 million to 2 million shares, accounting for 0.58 percent to 1.06 percent of the total share capital. The repurchase period will not exceed 12 months from the date the board of directors approves the plan. In the first quarter of 2026, the company achieved revenue of 189 million yuan and a net profit attributable to the parent company of 13.17 million yuan.
Zhejiang Shengda PharmCompany announces share buyback plan worth 16.5-30 million yuan, signaling confidence and supporting stock price.